Skip to content

Study Details

CAP-1002: A Study Drug for Human Allogeneic Cardioshere-Derived Cells for People with Duchenne Muscular Dystrophy (DMD)

(IRB#: IRB_00150933)

Duchenne Muscular Dystrophy (DMD) is a disease that weakens people's muscles over time. CAP-1002 is a study drug to help people with this disease. Research is needed to learn the safety and effectiveness of the drug. This information we gain may aid future patients.


  • Male Only
  • Over 7 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: Male Only

  Age: Over 7 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 10 years and older
  • Duchenne Muscular Dystrophy (DMD) diagnosis
  • Taking medication such as prednisone for at least 12 months, and must have stable health for at least 6 months
  • Receiving care at a credible multidisciplinary DMD center
  • In-person at the University of Utah

Exclusion Criteria

  • Already received other specific treatments at 3, 6, or 12 months
  • History or current drug or alcohol abuse
  • Use metformin or insulin within 3 months before participation
  • Severe illness 30 days before participation
  • Planned surgery 6 months during participation

Will I be paid for my time?


For more information contact:

Sarah Moldt


IRB#: IRB_00150933

PI: Russell Butterfield


Approval Date: 2022-09-15 06:00:00

Study Categories: Brain Health Studies

Specialties: Neurology

Last Updated: 6/8/23